Gene Therapy Shows Promise for Fatal Childhood Brain Disease GM1 Gangliosidosis

GM1 gangliosidosis is a devastating inherited brain disease that kills children by causing progressive neurodegeneration. The condition results from mutations in the GLB1 gene, which normally produces β-galactosidase, an enzyme that breaks down GM1 ganglioside in brain cells. Without this enzyme, toxic gangliosides accumulate and destroy neurons.

Researchers conducted a phase 1/2 trial testing AAV9 gene therapy in nine children aged 6 months to 12 years with Type II GM1 gangliosidosis. The treatment involved a single intravenous infusion of engineered virus particles carrying a functional copy of the GLB1 gene. Five children received a lower dose and four received a higher dose, with immunosuppressive drugs given to prevent immune rejection.

The therapy proved remarkably safe over three years of follow-up. Only one serious side effect occurred - vomiting requiring hospitalization for IV fluids. Liver enzymes temporarily increased but returned to baseline within 18 months. Most importantly, the treatment showed biological activity: all children developed measurable β-galactosidase enzyme in their cerebrospinal fluid, and toxic GM1 ganglioside levels decreased.

Clinically, children showed stabilized development rather than the expected continued decline. Brain MRI scans revealed improved myelination and reduced brain atrophy compared to natural history. Magnetic resonance spectroscopy showed preservation of N-acetylaspartate, a marker of healthy neurons that typically declines in this disease.

While not curative, this represents the first potential therapy for GM1 gangliosidosis. The results suggest gene therapy can slow or halt disease progression when given early enough, offering hope for families facing this previously untreatable condition.